A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

Participation in the 340B Drug Pricing Program does not increase the use of targeted therapy in older patients with advanced prostate cancer, a study suggests.

Linavonkibart is under clinical development by Scholar Rock and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success ...

BNT-325 is under clinical development by BioNTech and currently in Phase II for Castration-Resistant Prostate Cancer (CRPC).

Francis Medical Inc., a Twin Cities med-tech manufacturer that's developing a way to treat prostrate and other cancers with water vapor, said Tuesday it raised $80 million in its latest equity funding ...

Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double ...

New research from the IU School of Medicine found a discovery that could lead to new treatments for prostate cancer. The ...

The drug is already approved to treat non-metastatic castration-resistant prostate cancer (CRPC), but expansion into hormone-sensitive prostate cancer could unlock a sizeable new market for the drug.

Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...

Most patients with metastatic prostate cancer receive drugs that block production of androgen, which promotes cancer cell proliferation. These drugs rarely actually cure cancer, however ...

The identification of new drug resistance mechanisms and prostate cancer molecular subtypes based on genomic and proteomic analysis, as well as prognostic and predictive biomarkers, may further ...